SMT202200254T1 - Metodi di trattamento di fibromi uterini ed endometriosi - Google Patents

Metodi di trattamento di fibromi uterini ed endometriosi

Info

Publication number
SMT202200254T1
SMT202200254T1 SM20220254T SMT202200254T SMT202200254T1 SM T202200254 T1 SMT202200254 T1 SM T202200254T1 SM 20220254 T SM20220254 T SM 20220254T SM T202200254 T SMT202200254 T SM T202200254T SM T202200254 T1 SMT202200254 T1 SM T202200254T1
Authority
SM
San Marino
Prior art keywords
endometriosis
methods
uterine fibroids
treating uterine
treating
Prior art date
Application number
SM20220254T
Other languages
English (en)
Italian (it)
Inventor
Brendan Mark Johnson
Lynn Seely
Jr Paul N Mudd
Susan Wollowitz
Mark Hibberd
Masataka Tanimoto
Vijaykumar Reddy Rajasekhar
Mayukh Vasant Sukhatme
Original Assignee
Takeda Pharmaceuticals Co
Myovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202200254(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co, Myovant Sciences Gmbh filed Critical Takeda Pharmaceuticals Co
Publication of SMT202200254T1 publication Critical patent/SMT202200254T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
SM20220254T 2016-09-30 2017-09-29 Metodi di trattamento di fibromi uterini ed endometriosi SMT202200254T1 (it)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662402055P 2016-09-30 2016-09-30
US201662402150P 2016-09-30 2016-09-30
US201662402034P 2016-09-30 2016-09-30
US201762492839P 2017-05-01 2017-05-01
US201762528409P 2017-07-03 2017-07-03
EP17823018.1A EP3518933B2 (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis
PCT/EP2017/074907 WO2018060501A2 (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis

Publications (1)

Publication Number Publication Date
SMT202200254T1 true SMT202200254T1 (it) 2022-07-21

Family

ID=60915460

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20220254T SMT202200254T1 (it) 2016-09-30 2017-09-29 Metodi di trattamento di fibromi uterini ed endometriosi

Country Status (24)

Country Link
US (4) US11033551B2 (enExample)
EP (2) EP4094766B1 (enExample)
JP (1) JP7043503B2 (enExample)
CN (1) CN110312512B (enExample)
AU (2) AU2017336363B2 (enExample)
BR (1) BR112019006227A2 (enExample)
CA (1) CA3038879A1 (enExample)
CY (1) CY1125254T1 (enExample)
DK (1) DK3518933T4 (enExample)
ES (2) ES2912929T5 (enExample)
FI (1) FI3518933T4 (enExample)
HR (1) HRP20220708T4 (enExample)
HU (2) HUE072130T2 (enExample)
IL (2) IL300580B2 (enExample)
LT (1) LT3518933T (enExample)
MD (1) MD3518933T4 (enExample)
MX (1) MX2019003726A (enExample)
NZ (1) NZ752916A (enExample)
PL (2) PL3518933T5 (enExample)
PT (1) PT3518933T (enExample)
RS (1) RS63300B2 (enExample)
SI (1) SI3518933T2 (enExample)
SM (1) SMT202200254T1 (enExample)
WO (1) WO2018060501A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
EP3518932B1 (en) 2016-09-30 2024-11-13 Sumitomo Pharma Switzerland GmbH Treatment of prostate cancer
ES3018358T3 (es) 2017-06-05 2025-05-16 Kissei Pharmaceutical Régimen de dosificación que comprende un antagonista de la hormona liberadora de gonadotropina para tratar fibromas uterinos y reducir la pérdida de sangre menstrual
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
AU2018419533A1 (en) * 2018-04-19 2020-11-12 Abbvie Inc. Methods of treating heavy menstrual bleeding
MA54058A (fr) * 2018-10-29 2021-09-08 ObsEva SA Compositions et méthodes de traitement de l'endométriose interne et de l'endométriose rectovaginale
RU2711658C1 (ru) * 2019-04-16 2020-01-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения наружного генитального эндометриоза
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
JP2022543308A (ja) * 2019-08-08 2022-10-11 オブセヴァ エス.エー. エストロゲン依存性障害の治療のための組成物及び方法
CN115279769A (zh) * 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
EP4041738A1 (en) * 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
IL295781A (en) * 2020-02-19 2022-10-01 Aspira Women’S Health Inc Preparations with improved specificity for the evaluation of endometriosis
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
AU2021278303A1 (en) * 2020-05-29 2023-02-09 Sumitomo Pharma Switzerland Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN117069735A (zh) * 2022-05-10 2023-11-17 北京海美源医药科技有限公司 一种高效合成瑞卢戈利的方法和其应用
WO2024015934A2 (en) * 2022-07-13 2024-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of diagnostic screening and early detection of adenomyosis
WO2024102620A2 (en) * 2022-11-09 2024-05-16 Tempest Therapeutics, Inc. Triazolone compounds and uses thereof
WO2025106820A1 (en) * 2023-11-16 2025-05-22 University Of South Florida Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US402055A (en) 1889-04-23 Water-motor
US492839A (en) 1893-03-07 Key for brake-shoes
US402150A (en) 1889-04-30 Broadcast seed-sower
US402034A (en) 1889-04-23 Dumping-wagon
US528409A (en) 1894-10-30 Denis ahern
FR2512732A1 (fr) 1981-09-14 1983-03-18 Raffinage Cie Francaise Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
ECSP961635A (es) 1996-01-11 1997-06-27 Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es) 1997-01-15 1998-04-07 Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de) 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
AU2001234188A1 (en) 2000-02-29 2001-09-12 Takeda Chemical Industries Ltd. Processes for the production of thienopyrimidine derivatives
WO2003064429A1 (en) 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, process for preparing the same and use thereof
KR101074462B1 (ko) 2003-01-29 2011-10-18 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 화합물 및 그 용도
KR101139148B1 (ko) 2003-07-07 2012-04-26 뉴로크린 바이오사이언시즈 인코퍼레이티드 고나도트로핀-방출 호르몬 수용체 길항제로서의피리미딘-2,4-디온 유도체
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
NZ566038A (en) 2005-07-22 2011-06-30 Takeda Pharmaceutical The use of thieno(2,3-d)pyrimidine-2,4-dione derivatives which are gonadotropin releasing hormone (GnRH) antagonists as premature ovulation preventive agent
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
ES2534573T3 (es) 2007-04-06 2015-04-24 Neurocrine Biosciences, Inc. Antagonistas del receptor de la hormona liberadora de gonadotropina y métodos relacionados con los mismos
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
EP2329823A4 (en) 2008-09-03 2013-04-03 Takeda Pharmaceutical PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2011156908A1 (en) 2010-06-16 2011-12-22 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
JP2012077020A (ja) 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとGnRHアンタゴニストとの組合せ医薬
HRP20190729T1 (hr) 2012-09-28 2019-06-14 Takeda Pharmaceutical Company Limited Metoda proizvodnje derivata tienopirimidina
EP2968566A1 (en) 2013-03-15 2016-01-20 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding and uterine fibroids
ES2988678T3 (es) 2015-02-26 2024-11-21 Takeda Pharmaceuticals Co Un comprimido que comprende un derivado de metoxiurea y partículas de manitol
CA3002791A1 (en) 2015-09-01 2017-03-09 Abbvie Inc. Methods of administering elagolix
WO2018060501A2 (en) 2016-09-30 2018-04-05 Myovant Sciences Gmbh Methods of treating uterine fibroids and endometriosis
EP3518932B1 (en) 2016-09-30 2024-11-13 Sumitomo Pharma Switzerland GmbH Treatment of prostate cancer
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
CN115279769A (zh) 2019-10-10 2022-11-01 梦欧文科学有限责任公司 N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
EP4041738A1 (en) 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
AU2021278303A1 (en) 2020-05-29 2023-02-09 Sumitomo Pharma Switzerland Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Also Published As

Publication number Publication date
FI3518933T4 (fi) 2025-05-14
CN110312512A (zh) 2019-10-08
AU2022241582B2 (en) 2024-06-13
ES2912929T5 (en) 2025-05-09
ES3018413T3 (es) 2025-05-16
PL3518933T5 (pl) 2025-05-05
RS63300B2 (sr) 2025-05-30
DK3518933T3 (da) 2022-05-30
EP3518933A2 (en) 2019-08-07
JP2019529575A (ja) 2019-10-17
HUE059101T2 (hu) 2022-10-28
NZ752916A (en) 2022-09-30
CA3038879A1 (en) 2018-04-05
US20220370462A1 (en) 2022-11-24
EP3518933B1 (en) 2022-03-16
AU2017336363B2 (en) 2022-08-04
SI3518933T1 (sl) 2022-06-30
US20240165118A1 (en) 2024-05-23
BR112019006227A2 (pt) 2019-06-18
IL300580B1 (en) 2025-07-01
US20190262346A1 (en) 2019-08-29
CN110312512B (zh) 2023-05-09
PL4094766T3 (pl) 2025-07-28
MX2019003726A (es) 2019-09-26
AU2022241582A1 (en) 2022-10-27
HRP20220708T1 (hr) 2022-07-22
IL265700B2 (en) 2023-07-01
HUE072130T2 (hu) 2025-10-28
RS63300B1 (sr) 2022-07-29
SI3518933T2 (sl) 2025-05-30
IL265700B1 (en) 2023-03-01
MD3518933T2 (ro) 2022-07-31
AU2017336363A1 (en) 2019-05-16
EP4094766A1 (en) 2022-11-30
EP3518933B2 (en) 2025-02-26
IL300580B2 (en) 2025-11-01
PL3518933T3 (pl) 2022-06-20
JP7043503B2 (ja) 2022-03-29
US11957684B2 (en) 2024-04-16
US11793812B2 (en) 2023-10-24
AU2022241582C1 (en) 2024-11-28
US20210401841A1 (en) 2021-12-30
IL265700A (en) 2019-05-30
CY1125254T1 (el) 2024-02-16
EP4094766B1 (en) 2025-04-02
PT3518933T (pt) 2022-05-10
WO2018060501A3 (en) 2018-05-11
LT3518933T (lt) 2022-06-10
DK3518933T4 (da) 2025-04-22
US11033551B2 (en) 2021-06-15
IL300580A (en) 2023-04-01
HRP20220708T4 (hr) 2025-04-25
ES2912929T3 (es) 2022-05-30
WO2018060501A2 (en) 2018-04-05
MD3518933T4 (ro) 2025-10-31

Similar Documents

Publication Publication Date Title
IL265700A (en) Methods for treating uterine fibroids and endometrial disease
SG11201803619VA (en) Three-dimensional memory apparatuses and methods of use
GB2531863B (en) Security device and method of manufacture thereof
IL272570A (en) Methods and preparations for the detection and treatment of endometriosis
IL265359A (en) Modified Oligonucleotides and Methods of Use
ZA201802902B (en) Methods and apparatuses for configuration of measurement restrictions
IL252726A0 (en) Uterine clamps to treat postpartum bleeding and to help restore the uterus
GB2550168B (en) Security device and method of manufacture
SG10201405193QA (en) Hair extension device and related methods of manufacture
GB201620675D0 (en) Photociode device and method of manufacture
IL259096A (en) Peptides and methods of treating endometriosis using the same
GB2536877B (en) Security device and method of manufacture
GB2566975B (en) Security Device And Method Of Manufacture Thereof
HUE060394T2 (hu) Készítmények és módszerek az endometriózis kezelésére
GB2526531B (en) Security device components and methods of manufacture thereof
SG10201702547QA (en) Methods of vibro-treating and vibro-treating apparatus
IL274190A (en) Methods for treating ischemic disease
IL248381A0 (en) A combination of brexpiprazole and nalemapine and its use in the treatment of drug-related disorders
IL246637A0 (en) Preparations and methods for the treatment of intracerebral hemorrhage
PL3328529T3 (pl) Urządzenie do mieszania masy formierskiej i sposób mieszania masy formierskiej
GB2527908B (en) Closure means and method of use thereof
HK40012837A (en) Methods of treating uterine fibroids and endometriosis
GB2556880B (en) Security device components and methods of manufacture thereof
GB201600264D0 (en) Fixation device location and method of manufacture and use